PHASE II STARLITE-2 STUDY

Starlite-2 (Phase II, Recruiting)

  • Study title: A Phase 2 Open-label Study of Nivolumab Combined With Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients With Clear Cell Advanced Renal Cell Carcinoma
  • Study description: A Phase II trial evaluating the combination therapy of 177Lu-TLX250 with ipilimumab+nivolumab in metastatic ccRCC patients who have progressed on initial checkpoint inhibitor or TKI therapy. Endpoints include safety and tolerability and objective response rate with this combination.
  • Trial status: Recruiting
  • Trial identifier: NCT05239533
  • Sponsor: Telix International Pty Ltd
  • Investigational asset: 177Lu-labeled-girentuximab
  • Condition: Clear Cell Renal Cell Carcinoma
  • Ages eligible for study: ≥18 years
  • Gender: All
  • No healthy volunteers

CLINICAL RATIONALE

PRIMARY OUTCOME MEASURES

ELIGIBILITY: INCLUSION CRITERIA

ELIGIBILITY: EXCLUSION CRITERIA

GET IN TOUCH FOR MORE ON THE TRIALS